

Global Clinical Development Pipeline

Updated: 20 March 2025

Phase 1		Phase 2		Phase 3		Accepted Submissions	
Sonrotoclax ● 101 B-cell malignancies ● 102 B-cell malignancies ● 103 AML/MDS ● 105 R/R MM t(11;14) ● 108 Dose ramp-up	BCL2i	BGB-16673 ● 101 B-cell malignancies ● 102 B-cell malignancies ● 104 B-cell malignancies	BTK CDAC	Zanubrutinib ● 215 B-cell malignancies ● 218 CD79B R/R DLBCL	BTKi	Zanubrutinib ● 306 TN MCL ● 308 R/R MZL, R/R FL ● 309 pMN	BTKi
BGB-43395 ● 101/102 BC & Solid tumors	CDK4i	BGB-21447 ● 101 B-cell malignancies ● 102 Metastatic breast cancer	BCL2i 2G	BGB-16673 ● 101 R/R CLL ● 102 R/R CLL	BTK CDAC	BGB-16673 ● 302 R/R CLL	BTK CDAC
BGB-53038 ● 101 Solid tumors	PanKRASi	Xaluritamig⁴ ● 20180146 mCRPC	STEAP1 x CD3 XmAb[®]	Sonrotoclax ● 201 R/R MCL ● 202 R/R CLL ● 203 R/R WM ● 204 TN CLL/SLL	BCL2i	Sonrotoclax ● 301 TN CLL ● 302 R/R MCL	BCL2i
BG-C9074¹ ● 101 Solid tumors	B7H4 ADC	BGB-R046 ● 101 Solid tumors	IL-15 prodrug	Blinatumomab⁴ ● 20190359 Pediatric R/R BP-ALL	CD3 x CD19 BiTE[®]	Tislelizumab ● 310 1L UBC ● 314 R/R cHL	PD1 mAb
BG-60366 ● 101 Solid tumors	EGFR CDAC	BGB-B2033 ● 101 Solid tumors	GPC3 x 4-1BB BsAb	LBL-007⁵ ● 201 MSS-CRC ● 202 1L ESCC	LAG3 mAb	Pamiparib ● 302 2L MTx gBRCAm PSOC	PARPi
BG-58067 ● 101 Solid tumors	MTA Coop. PRMT5i	BGB-B3227 ● 101 Solid tumors	MUC1 x CD16A BsAb	BGB-A445 ● 201 Melanoma, UC	OX40 mAb	Ociperlimab ● 302 1L NSCLC PDL1-high	TIGIT mAb
BG-89894² ● 101 Solid tumors	MAT2Ai	BGB-15025 ● 101 Solid tumors	HPK1i	Umbrella Studies ● LC-201 1L NSCLC ● HNSCC-201 1L HNSCC	IO Combos	Zanidatamab⁶ ● 301 1L HER2+ GEA	HER2 BsAb
BGB-45035 ● 101 Immunology & Inflammation	IRAK4 CDAC	BGB-26808 ● 101 Solid tumors	HPK1i	Tarlatamab⁴ ● 20230273 3L SCLC	DLL3 x CD3 BiTE[®]	Tarlatamab⁴ ● 20210004 2L SCLC ● 20200041 1L ES-SCLC ● 20230016 LS-SCLC	DLL3 x CD3 BiTE[®]
BG-68501³ ● 101 BC & Solid tumors	CDK2i	BGB-30813 ● 101 Solid tumors	DGKζi				
BG-C354 ● 101 Solid tumors	B7H3 ADC	BGB-A3055 ● 101 Solid tumors	CCR8 mAb				
BG-C477 ● 101 Solid tumors	CEA ADC	BGB-24714 ● 101 Solid tumors	SMAC mimetic				
BG-C137 ● 101 Solid tumors	FGFR2b ADC	Tislelizumab ● 103 SubQ formulation	PD1 mAb				
BG-T187 ● 101 Solid tumors	EGFR x MET TsAb	BGB-B455 ● 101 Solid tumors	CLDN6 x CD3 BsAb				

- Heme
- Breast / Gyn
- Pan-Tumor / Other
- Lung
- GI
- Non-Oncology

Accepted submissions only shown for major markets US, CN, EU, JP.
 1) DualityBio collaboration, 2) CSPC collaboration, 3) Ensem collaboration, 4) Amgen collaboration, 5) Leads Biolabs collaboration, 6) Zymeworks/Jazz collaboration.
 Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details

